CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02598427
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:39.940964+00:00
Published At: 2018-02-28T00:00:00+00:00
Record Updated At: 2018-02-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["HER2 Positive Untreated Metastatic Breast Cancer", "Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-02-28"
protocolSection.identificationModule.nctId: "NCT02598427"
protocolSection.identificationModule.officialTitle: "Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.